Precise pathologic criteria for the diagnosis of mycosis fungoides (MF) remain controversial. With the use of a specific counting technique and defined criteria for cell types, we attempted to differentiate between a series of slides from patients with eczematous dermatitis, large plaque parapsoriasis, and atypical dermatitis with features that suggest MF, the plaque stage of MF, and the tumor stage of MF. This could not be done on the basis of cellular density in e defined field in the papillary dermis or on the basis of the percentage of atypical lymphocytes in the fields counted. Furthermore, individual investigator variance was shown to be highly significant despite efforts to minimize this factor.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Progression of Mycosis Fungoides During Treatment with Mogamulizumab: A BIO-MUSE Case Study of the Tumor and Immune Response in Peripheral Blood and Tissue.
Biomedicines
January 2025
Department of Immunotechnology, Faculty of Engineering (LTH), Lund University, 223 63 Lund, Sweden.
Article Synopsis
- Mycosis fungoides (MF) is a rare skin cancer that progresses slowly in early stages but can vary greatly in treatment response and life expectancy once advanced.
- The BIO-MUSE trial aims to identify specific markers for disease progression using advanced molecular analysis techniques, analyzing tissue and blood samples from a patient over time.
- Findings highlight potential targets for treatment, such as transforming growth factor β1, suggesting that studying the cancer's evolution alongside the immune response may improve future interventions.
Primary Cutaneous Methotrexate-Associated T-Cell Lymphoproliferative Disorder in the Setting of Autoimmune Disease: A Case Series and Review of the Literature.
Am J Dermatopathol
February 2025
Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
Methotrexate (MTX), an antimetabolite targeting certain autoimmune conditions and various hematologic malignancies, has been associated with iatrogenic lymphoproliferative disease (LPD) primarily of B-cell lineage. Less commonly are T-cell neoplasms where primary skin involvement is considered rare. Three cases were encountered in the medical practice of one of the authors.
View Article and Find Full Text PDFThe notch sign as a clue for the diagnosis of early cutaneous T-cell lymphoma.
JAAD Case Rep
February 2025
Department of Dermatology, Cliniques universitaires Saint-Luc UCLouvain, Brussels, Belgium.
Hypopigmented mycosis fungoides: an important differential diagnosis of hypochromias in childhood.
Rev Paul Pediatr
January 2025
Universidade do Estado do Pará, Belém, PA, Brazil.
Objective: To highlight the importance of early recognition of hypopigmented mycosis fungoides (HMF) in cases of cutaneous hypochromia in children, with a view to an effective diagnostic and therapeutic approach.
Case Description: Two cases of HMF in children are reported. The first case involves an eight-year-old boy with hypochromic macules on the trunk and root of the upper and lower limbs, while the second case is a six-year-old boy with widespread hypochromic patches.
Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.
J Dtsch Dermatol Ges
January 2025
Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Background And Objectives: Patients with cutaneous lymphomas (CL) are at an increased risk of developing secondary malignancies. This study aimed to assess the frequency of association between CL and Kaposi sarcoma (KS) and to identify factors that may promote the co-occurrence of these two diseases.
Patients And Methods: On January 25, 2024, we conducted a systematic search of four electronic medical databases to identify all published cases of KS associated with CL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!